Esther S. Pronker
Research Subjects
Research Interests
Esther S. Pronker has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- H.R. Commandeur
Erasmus University Rotterdam, Faculty of Economics, The Netherlands
3 shared publications - Tamar C. Weenen
Erasmus University, The Netherlands
3 shared publications A.D.M.E. Osterhaus
Erasmus Medical Centre Rotterdam, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands
2 shared publicationsE. Claassen
Erasmus University, The Netherlands
2 shared publications- Eric Claassen
Athena Institute, Vrije Universiteit
2 shared publications Adam Cohen
Centre for Human Drug Research, Leiden
1 shared publication
Latest Publications
- 31 July 2014
- Published by Elsevier in PharmaNutrition
- Vol. 2 (3) , 93
Knowledge diffusion in the European medical nutrition industry
- 31 July 2014
- Published by Elsevier in PharmaNutrition
- Vol. 2 (3) , 93
Knowledge diffusion in the European medical nutrition industry
- Open Access
- 20 March 2013
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (3) , e57755
Risk in Vaccine Research and Development Quantified
To date, vaccination is the most cost-effective strategy to combat infectious diseases. Recently, a productivity gap affects the pharmaceutical industry. The productivity gap describes the situation whereby the invested resources within an industry do not match the expected product turn-over. While risk profiles (combining research and development timelines and transition rates) have been published for new chemical entities (NCE), little is documented on vaccine development. The objective is to calculate risk profiles for vaccines targeting human infectious diseases. A database was actively compiled to include all vaccine projects in development from 1998 to 2009 in the pre-clinical development phase, clinical trials phase I, II and III up to Market Registration. The average vaccine, taken from the preclinical phase, requires a development timeline of 10.71 years and has a market entry probability of 6%. Stratification by disease area reveals pandemic influenza vaccine targets as lucrative. Furthermore, vaccines targeting acute infectious diseases and prophylactic vaccines have shown to have a lower risk profile when compared to vaccines targeting chronic infections and therapeutic applications. In conclusion; these statistics apply to vaccines targeting human infectious diseases. Vaccines targeting cancer, allergy and autoimmune diseases require further analysis. Additionally, this paper does not address orphan vaccines targeting unmet medical needs, whether projects are in-licensed or self-originated and firm size and experience. Therefore, it remains to be investigated how these - and other - variables influence the vaccine risk profile. Although we find huge differences between the risk profiles for vaccine and NCE; vaccines outperform NCE when it comes to development timelines.
- 20 March 2013
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (3) , e57755
Open AccessRisk in Vaccine Research and Development Quantified
To date, vaccination is the most cost-effective strategy to combat infectious diseases. Recently, a productivity gap affects the pharmaceutical industry. The productivity gap describes the situation whereby the invested resources within an industry do not match the expected product turn-over. While risk profiles (combining research and development timelines and transition rates) have been published for new chemical entities (NCE), little is documented on vaccine development. The objective is to calculate risk profiles for vaccines targeting human infectious diseases. A database was actively compiled to include all vaccine projects in development from 1998 to 2009 in the pre-clinical development phase, clinical trials phase I, II and III up to Market Registration. The average vaccine, taken from the preclinical phase, requires a development timeline of 10.71 years and has a market entry probability of 6%. Stratification by disease area reveals pandemic influenza vaccine targets as lucrative. Furthermore, vaccines targeting acute infectious diseases and prophylactic vaccines have shown to have a lower risk profile when compared to vaccines targeting chronic infections and therapeutic applications. In conclusion; these statistics apply to vaccines targeting human infectious diseases. Vaccines targeting cancer, allergy and autoimmune diseases require further analysis. Additionally, this paper does not address orphan vaccines targeting unmet medical needs, whether projects are in-licensed or self-originated and firm size and experience. Therefore, it remains to be investigated how these - and other - variables influence the vaccine risk profile. Although we find huge differences between the risk profiles for vaccine and NCE; vaccines outperform NCE when it comes to development timelines.
- 31 January 2013
- Published by Elsevier in PharmaNutrition
- Vol. 1 (1) , 13-21
Patenting in the European medical nutrition industry: Trends, opportunities and strategies
- 31 January 2013
- Published by Elsevier in PharmaNutrition
- Vol. 1 (1) , 13-21
Patenting in the European medical nutrition industry: Trends, opportunities and strategies
- 1 February 2011
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 71 (3) , 467-470
Improving the quality of drug research or simply increasing its cost? An evidence‐based study of the cost for data monitoring in clinical trials
Procedures for verification of data from clinical studies are intended to maintain reliability for clinical trial results. Guidelines or legislations relating to clinical data management are of limited value and no study has yet demonstrated its effectiveness. Sponsor queries and dual entry procedures from one CRO on three different phase I trials are analysed on content, impact and cost. In this study, sponsor queries and dual entry procedures proved time and cost inefficient in detecting data discrepancies. We advocate a more evidence-based approach for enhancing data integrity throughout the process of clinical data management.
- 1 February 2011
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 71 (3) , 467-470
Improving the quality of drug research or simply increasing its cost? An evidence‐based study of the cost for data monitoring in clinical trials
Procedures for verification of data from clinical studies are intended to maintain reliability for clinical trial results. Guidelines or legislations relating to clinical data management are of limited value and no study has yet demonstrated its effectiveness. Sponsor queries and dual entry procedures from one CRO on three different phase I trials are analysed on content, impact and cost. In this study, sponsor queries and dual entry procedures proved time and cost inefficient in detecting data discrepancies. We advocate a more evidence-based approach for enhancing data integrity throughout the process of clinical data management.